
Sign up to save your podcasts
Or
On this special episode we’re discussing the new FDA-approved drug Kisunla (donanemab) for the treatment of people living with early symptomatic Alzheimer’s disease. We’re joined by Dr. Margarita Reyes, a physician at Bristol Health Group in Connecticut, who explains how Kisunla works, the difference between Kisunla and Leqembi, side effects, and much more.
Need assistance? Call the Alzheimer’s Association 24/7 Helpline (800.272.3900).
5
77 ratings
On this special episode we’re discussing the new FDA-approved drug Kisunla (donanemab) for the treatment of people living with early symptomatic Alzheimer’s disease. We’re joined by Dr. Margarita Reyes, a physician at Bristol Health Group in Connecticut, who explains how Kisunla works, the difference between Kisunla and Leqembi, side effects, and much more.
Need assistance? Call the Alzheimer’s Association 24/7 Helpline (800.272.3900).
38,153 Listeners
27,333 Listeners
30,951 Listeners
22,070 Listeners
43,470 Listeners
3,452 Listeners
2,603 Listeners
9,378 Listeners
8,218 Listeners
57,800 Listeners
4,361 Listeners
2,044 Listeners
9,556 Listeners
17 Listeners
5,110 Listeners